Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:EDIT NASDAQ:LENZ NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$2.13+2.2%$1.64$1.05▼$3.56$90.95M2.011.48 million shs133,632 shsEDITEditas Medicine$3.14+3.1%$2.63$1.29▼$4.54$307.83M2.141.68 million shs456,176 shsLENZLENZ Therapeutics$9.22+1.6%$10.60$8.25▼$50.40$288.98M0.62986,843 shs194,761 shsZNTLZentalis Pharmaceuticals$4.04-1.3%$3.22$1.13▼$6.95$287.25M1.992.01 million shs264,000 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-0.48%+9.47%+36.84%+23.08%+46.48%EDITEditas Medicine+4.83%-0.65%+13.86%+55.90%+97.40%LENZLENZ Therapeutics+2.14%-2.37%-6.20%-37.96%-68.83%ZNTLZentalis Pharmaceuticals0.00%+0.99%+55.51%+60.39%+200.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$2.13+2.2%$1.64$1.05▼$3.56$90.95M2.011.48 million shs133,632 shsEDITEditas Medicine$3.14+3.1%$2.63$1.29▼$4.54$307.83M2.141.68 million shs456,176 shsLENZLENZ Therapeutics$9.22+1.6%$10.60$8.25▼$50.40$288.98M0.62986,843 shs194,761 shsZNTLZentalis Pharmaceuticals$4.04-1.3%$3.22$1.13▼$6.95$287.25M1.992.01 million shs264,000 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-0.48%+9.47%+36.84%+23.08%+46.48%EDITEditas Medicine+4.83%-0.65%+13.86%+55.90%+97.40%LENZLENZ Therapeutics+2.14%-2.37%-6.20%-37.96%-68.83%ZNTLZentalis Pharmaceuticals0.00%+0.99%+55.51%+60.39%+200.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 2.50Moderate Buy$11.67449.02% UpsideEDITEditas Medicine 2.57Moderate Buy$5.4072.25% UpsideLENZLENZ Therapeutics 2.63Moderate Buy$44.00377.48% UpsideZNTLZentalis Pharmaceuticals 2.29Hold$5.8344.57% UpsideCurrent Analyst Ratings BreakdownLatest ACRV, LENZ, EDIT, and ZNTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.004/27/2026ACRVAcrivon Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026LENZLENZ Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $48.004/20/2026EDITEditas Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026ZNTLZentalis Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $10.004/7/2026ZNTLZentalis Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ZNTLZentalis Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.003/26/2026LENZLENZ Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $26.003/25/2026LENZLENZ Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$35.00 ➝ $29.003/17/2026ZNTLZentalis Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$5.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$3.57 per shareN/AEDITEditas Medicine$40.52M7.58N/AN/A$0.28 per share11.20LENZLENZ Therapeutics$19.09M15.13N/AN/A$9.09 per share1.01ZNTLZentalis Pharmaceuticals$67.43M4.26N/AN/A$2.99 per share1.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$77.90M-$2.02N/AN/AN/AN/A-57.23%-51.09%5/13/2026 (Estimated)EDITEditas Medicine-$160.06M-$1.89N/AN/AN/A-395.02%-389.73%-55.28%5/11/2026 (Estimated)LENZLENZ Therapeutics-$82.13M-$2.81N/AN/AN/AN/A-37.47%-35.13%5/6/2026 (Estimated)ZNTLZentalis Pharmaceuticals-$137.06M-$1.90N/AN/AN/AN/A-52.77%-40.55%5/13/2026 (Estimated)Latest ACRV, LENZ, EDIT, and ZNTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ACRVAcrivon Therapeutics-$0.49N/AN/AN/A$0.28 millionN/A5/13/2026Q1 2026ZNTLZentalis Pharmaceuticals-$0.49N/AN/AN/AN/AN/A5/11/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million5/6/2026Q1 2026LENZLENZ Therapeutics-$1.10N/AN/AN/A$1.76 millionN/A3/26/2026Q4 2025ZNTLZentalis Pharmaceuticals-$0.41-$0.49-$0.08-$0.49N/AN/A3/24/2026Q4 2025LENZLENZ Therapeutics-$0.91-$1.16-$0.25-$1.16$3.09 million$1.59 million3/19/2026Q4 2025ACRVAcrivon Therapeutics-$0.49-$0.49N/A-$0.49$0.17 millionN/A3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A7.697.69EDITEditas MedicineN/A3.543.54LENZLENZ TherapeuticsN/A14.2314.09ZNTLZentalis PharmaceuticalsN/A6.936.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%EDITEditas Medicine71.90%LENZLENZ Therapeutics54.32%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%EDITEditas Medicine1.90%LENZLENZ Therapeutics6.90%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5842.80 million35.45 millionNot OptionableEDITEditas Medicine23097.91 million96.05 millionOptionableLENZLENZ Therapeutics11031.35 million29.19 millionN/AZNTLZentalis Pharmaceuticals16071.19 million69.58 millionOptionableACRV, LENZ, EDIT, and ZNTL HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday2 hours ago | marketbeat.comZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerMay 5 at 8:00 AM | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comShort Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Grows By 22.2%April 30, 2026 | marketbeat.comZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerApril 21, 2026 | globenewswire.comZentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the TargetApril 20, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at ...April 18, 2026 | finance.yahoo.comZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026April 17, 2026 | globenewswire.comA Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection MilestoneApril 13, 2026 | finance.yahoo.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from BrokeragesApril 13, 2026 | marketbeat.comZentalis Pharmaceuticals, Inc. $ZNTL Shares Acquired by JPMorgan Chase & Co.April 11, 2026 | marketbeat.comWhat's behind the surge in Zentalis stock?April 10, 2026 | msn.comWhat's Behind The Surge In Zentalis Stock?April 10, 2026 | benzinga.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00April 10, 2026 | marketbeat.comZentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83April 10, 2026 | msn.comZentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian CancerApril 9, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comZentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational UpdatesMarch 26, 2026 | globenewswire.comZentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026March 17, 2026 | globenewswire.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesFebruary 18, 2026 | globenewswire.comVincent Vultaggio Sells 6,894 Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) StockFebruary 11, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026This AI Lender Has Big Upside Potential—And Big Risks By Peter Frank | April 19, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026CPI Card Group’s Quiet Cash Machine Faces a Digital Reality CheckBy Peter Frank | May 4, 2026ACRV, LENZ, EDIT, and ZNTL Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$2.12 +0.05 (+2.16%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Editas Medicine NASDAQ:EDIT$3.14 +0.10 (+3.13%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.LENZ Therapeutics NASDAQ:LENZ$9.22 +0.15 (+1.60%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Zentalis Pharmaceuticals NASDAQ:ZNTL$4.04 -0.06 (-1.34%) As of 11:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
